Does ABO Compatibility Predict Lung Transplant Outcomes?
NC Yu, MD; M Haug, PharmD: SU Khan, MD; AC Mehta, MBBS; T Kirby, MD: M Goormastic, MPH; JR Maurer, MD; The Cleveland Clinic Foundation Purpose: This study was conducted to assess and compare the outcomes of lung transplant recipient receiving ABO-identical (AI) with those receiving ABO-compatible (AC) allografts. Methonds: We completed a retrospective chart review of patients transplanted between 2/90 and 10/95. The median follow-up time was 22 (range = 0-78) months. Standard triple-drug immunosuppression regimen and general antimicrobial prophylaxis were provided. Surveillance spirometry was administered every 2-3 months. Fiberoptic bronchoscopy with transbronchial biopsies (TBBs) were undertaken for clinical indications. Surveillance TBBs were not performed. Time to event analysis on acute (AR) and chronic (CR) rejection and actuarial survival were determined by Kaplan-Meier analysis. Curves were compared with a log rank test between the AI and the AC cohorts. Comparisons of age, max
